IP Library Patent Application 13167836
Patent Application
App. No. 13/167,836

Compositions Comprising Quinolone and Methods for Treating or Controlling Infections

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/167,836
Abstract

Compositions for treating or controlling infections comprise a fluoroquinolone having Formulae I-VIII and have a pH in the range from about 3.5 to about 5.5 or from about 10.5 to about 12. Methods for treating or controlling such infection use such compositions. Such compositions and methods can deliver a higher amount of the fluoroquinolone to the affected site.

Claims (11)

1 . A method for treating or controlling an infection in a subject, the method comprising administering to a subject in need thereof, a composition comprising a fluoroquinolone having Formula I or salts thereof, wherein the composition has a pH in a range from about 3.5 to about 5.5 or from about 10.5 to about 12, and the fluoroquinolone is present in an amount effective to treat or control said infection,

wherein R 1 is selected from the group consisting of hydrogen, unsubstituted lower alkyl groups, substituted lower alkyl groups, cycloalkyl groups, unsubstituted C 5 -C 24 aryl groups, substituted C 5 -C 24 aryl groups, unsubstituted C 5 -C 24 heteroaryl groups, substituted C 5 -C 24 heteroaryl groups, and groups that can be hydrolyzed in living bodies; R 2 is selected from the group consisting of hydrogen, unsubstituted amino group, and amino groups substituted with one or two lower alkyl groups; R 3 is selected from the group consisting of hydrogen, unsubstituted lower alkyl groups, substituted lower alkyl groups, cycloalkyl groups, unsubstituted lower alkoxy groups, substituted lower alkoxy groups, unsubstituted C 5 -C 24 aryl groups, substituted C 5 -C 24 aryl groups, unsubstituted C 5 -C 24 heteroaryl groups, substituted C 5 -C 24 heteroaryl groups, unsubstituted C 5 -C 24 aryloxy groups, substituted C 5 -C 24 aryloxy groups, unsubstituted C 5 -C 24 heteroaryloxy groups, substituted C 5 -C 24 heteroaryloxy groups, and groups that can be hydrolyzed in living bodies; X is selected from the group consisting of halogen atoms; Y is selected from the group consisting of CH 2 , O, S, SO, SO 2 , and NR 4 , wherein R 4 is selected from the group consisting of hydrogen, unsubstituted lower alkyl groups, substituted lower alkyl groups, and cycloalkyl groups; and Z is selected from the group consisting of oxygen and two hydrogen atoms; and wherein the composition is capable of inhibiting a growth or survival of at least a bacterium causing said infection.

2 . The method of claim 1 , wherein the composition is administered topically, orally, or systemically.

3 . The method of claim 2 , wherein the composition is administered topically.

4 . The method of claim 3 , wherein the infection is an infection of an eye, an ear, a portion of a respiratory system, or a combination thereof.

5 . The method of claim 1 , wherein a microorganism causing the infection is a bacterium that is resistant to an antibacterial agent.

6 . The method of claim 1 , wherein the composition further comprises a quinolone other than the fluoroquinolones having Formula I, and wherein the additional anti-infective agent is selected from the group consisting of antiviral agents, antifungal agents, antiprotozoal agents, and mixtures thereof.

7 . A method for treating or controlling an infection in a subject, the method comprising administering to the subject in need thereof, a composition comprising: (a) a fluoroquinolone having Formula III or salts thereof; and (b) an additional anti-infective agent; wherein the composition has a pH in a range from about 3.5 to about 5.5 or from about 10.5 to about 12, and the fluoroquinolone has a concentration of from about 0.01 to about 1 percent by weight.

8 . The method of claim 7 , wherein the fluoroquinolone is a single enantiomer of the fluoroquinolone having Formula III.

9 . The method of claim 7 , wherein the composition is administered topically, orally, or systemically.

10 . The method of claim 7 , wherein the infection is an infection of an eye, an ear, a portion of a respiratory tract, or a combination thereof.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →